GC Biopharma (006280.KS) Stock Price

GC Biopharma Price

KOSDAQ·CLOSED
112,700.00KRW-1,600.00 (-1.41 %)
Market closed

Revenue has compounded at 8.3% per year over the past 19 years to 1.68 T KRW. Earnings per share have grown at 3.4% per year over the last 17 years. GC Biopharma's net margin stands at -1.6%, down from 5.4% several years earlier. GC Biopharma currently offers a dividend yield of about 1.33%. The dividend has grown at 6.0% per year over the past 19 years. Analysts set a median price target of 209,100.00 KRW, implying 85.5% above the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus.

GC Biopharma stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of GC Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how GC Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing GC Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

GC Biopharma Stock Price History
DateGC Biopharma Price
8/3/2026112,700.00 KRW
7/31/2026114,300.00 KRW
7/30/2026114,200.00 KRW
7/29/2026115,800.00 KRW
7/28/2026120,600.00 KRW
7/27/2026124,900.00 KRW
7/24/2026123,700.00 KRW
7/23/2026123,100.00 KRW
7/22/2026118,700.00 KRW
7/21/2026118,600.00 KRW
7/20/2026120,400.00 KRW
7/16/2026122,800.00 KRW
7/15/2026122,200.00 KRW
7/14/2026120,100.00 KRW
7/13/2026123,200.00 KRW
7/10/2026125,600.00 KRW
7/9/2026119,500.00 KRW
7/8/2026121,700.00 KRW
7/7/2026125,000.00 KRW
7/6/2026122,500.00 KRW
7/3/2026121,300.00 KRW
7/2/2026122,200.00 KRW
7/1/2026124,200.00 KRW
6/30/2026121,900.00 KRW
6/29/2026126,800.00 KRW
6/26/2026116,400.00 KRW
6/25/2026127,600.00 KRW
6/24/2026124,000.00 KRW
6/23/2026118,600.00 KRW
6/22/2026121,500.00 KRW
6/19/2026123,300.00 KRW
6/18/2026130,400.00 KRW
6/17/2026134,100.00 KRW
6/16/2026130,100.00 KRW
6/15/2026131,600.00 KRW
6/12/2026128,800.00 KRW
6/11/2026122,000.00 KRW
6/10/2026122,100.00 KRW
6/9/2026123,300.00 KRW
6/8/2026118,700.00 KRW
6/5/2026127,000.00 KRW
6/4/2026130,700.00 KRW
6/2/2026131,900.00 KRW
6/1/2026137,300.00 KRW
5/29/2026142,300.00 KRW
5/28/2026142,700.00 KRW
5/27/2026150,800.00 KRW
5/26/2026143,500.00 KRW
5/22/2026137,400.00 KRW
5/21/2026132,200.00 KRW
5/20/2026127,700.00 KRW
5/19/2026130,700.00 KRW
5/18/2026134,300.00 KRW
5/15/2026142,600.00 KRW
5/14/2026144,800.00 KRW
5/13/2026138,200.00 KRW
5/12/2026137,300.00 KRW
5/11/2026134,200.00 KRW
5/8/2026138,100.00 KRW
5/7/2026136,600.00 KRW
5/6/2026135,800.00 KRW
5/4/2026137,500.00 KRW
4/30/2026137,100.00 KRW
4/29/2026139,200.00 KRW
4/28/2026140,100.00 KRW
4/27/2026141,600.00 KRW
4/24/2026142,900.00 KRW
4/23/2026142,200.00 KRW
4/22/2026142,300.00 KRW
4/21/2026144,000.00 KRW
4/20/2026147,700.00 KRW
4/17/2026151,200.00 KRW
4/16/2026149,600.00 KRW
4/15/2026148,000.00 KRW
4/14/2026144,000.00 KRW
4/13/2026142,300.00 KRW
4/10/2026144,300.00 KRW
4/9/2026144,300.00 KRW
4/8/2026142,600.00 KRW
4/7/2026138,400.00 KRW
4/6/2026140,000.00 KRW
4/3/2026140,600.00 KRW
4/2/2026141,100.00 KRW
4/1/2026148,500.00 KRW
3/31/2026142,900.00 KRW
3/30/2026145,000.00 KRW
3/27/2026151,000.00 KRW
3/26/2026148,300.00 KRW
3/25/2026149,000.00 KRW
3/24/2026144,500.00 KRW
3/23/2026142,800.00 KRW
3/20/2026146,900.00 KRW
3/19/2026145,200.00 KRW
3/18/2026150,900.00 KRW
3/17/2026148,300.00 KRW
3/16/2026149,500.00 KRW
3/13/2026152,200.00 KRW
3/12/2026149,200.00 KRW
3/11/2026151,400.00 KRW
3/10/2026151,500.00 KRW
3/9/2026144,200.00 KRW
3/6/2026152,100.00 KRW
3/5/2026149,600.00 KRW
3/4/2026138,700.00 KRW
3/3/2026162,100.00 KRW
2/27/2026169,100.00 KRW
2/26/2026166,500.00 KRW
2/25/2026168,600.00 KRW
2/24/2026176,900.00 KRW
2/23/2026173,100.00 KRW
2/20/2026172,600.00 KRW
2/19/2026177,500.00 KRW
2/13/2026174,300.00 KRW
2/12/2026180,300.00 KRW
2/11/2026174,800.00 KRW
2/10/2026169,100.00 KRW
2/9/2026169,400.00 KRW
2/6/2026164,300.00 KRW
2/5/2026170,000.00 KRW
2/4/2026163,800.00 KRW
2/3/2026163,300.00 KRW
2/2/2026156,700.00 KRW
1/30/2026164,900.00 KRW
1/29/2026169,300.00 KRW
1/28/2026170,100.00 KRW
1/27/2026172,500.00 KRW
1/26/2026163,100.00 KRW
1/23/2026161,500.00 KRW
1/22/2026152,700.00 KRW
1/21/2026150,900.00 KRW
1/20/2026158,500.00 KRW
1/19/2026158,500.00 KRW
1/16/2026160,300.00 KRW
1/15/2026170,500.00 KRW
1/14/2026162,900.00 KRW
1/13/2026161,000.00 KRW
1/12/2026160,000.00 KRW
1/9/2026156,400.00 KRW
1/8/2026158,300.00 KRW
1/7/2026160,900.00 KRW
1/6/2026161,000.00 KRW
1/5/2026161,000.00 KRW
1/2/2026159,400.00 KRW
12/30/2025159,000.00 KRW
12/29/2025149,300.00 KRW
12/26/2025153,300.00 KRW
12/24/2025156,800.00 KRW
12/23/2025159,700.00 KRW
12/22/2025164,100.00 KRW
12/19/2025167,000.00 KRW
12/18/2025166,500.00 KRW
12/17/2025165,300.00 KRW
12/16/2025164,800.00 KRW
12/15/2025166,900.00 KRW
12/12/2025162,000.00 KRW
12/11/2025151,100.00 KRW
12/10/2025135,100.00 KRW
12/9/2025133,700.00 KRW
12/8/2025133,100.00 KRW
12/5/2025135,400.00 KRW
12/4/2025137,200.00 KRW
12/3/2025138,000.00 KRW
12/2/2025137,500.00 KRW
12/1/2025137,200.00 KRW
11/28/2025135,600.00 KRW
11/27/2025134,300.00 KRW
11/26/2025134,300.00 KRW
11/25/2025129,700.00 KRW
11/24/2025130,500.00 KRW
11/21/2025130,600.00 KRW
11/20/2025133,900.00 KRW
11/19/2025132,400.00 KRW
11/18/2025134,000.00 KRW
11/17/2025138,500.00 KRW
11/14/2025139,400.00 KRW
11/13/2025139,300.00 KRW
11/12/2025136,900.00 KRW
11/11/2025131,500.00 KRW
11/10/2025131,900.00 KRW
11/7/2025128,400.00 KRW
11/6/2025132,700.00 KRW
11/5/2025131,600.00 KRW
11/4/2025131,300.00 KRW
11/3/2025130,700.00 KRW
10/31/2025129,700.00 KRW
10/30/2025129,000.00 KRW
10/29/2025131,100.00 KRW
10/28/2025133,300.00 KRW
10/27/2025132,700.00 KRW
10/24/2025128,800.00 KRW
10/23/2025128,800.00 KRW
10/22/2025132,200.00 KRW
10/21/2025130,700.00 KRW
10/20/2025130,700.00 KRW
10/17/2025128,200.00 KRW
10/16/2025129,400.00 KRW
10/15/2025130,600.00 KRW
10/14/2025128,700.00 KRW
10/13/2025129,500.00 KRW
10/10/2025130,200.00 KRW
10/2/2025132,000.00 KRW
10/1/2025129,300.00 KRW
9/30/2025129,200.00 KRW
9/29/2025130,800.00 KRW
9/26/2025131,700.00 KRW
9/25/2025136,900.00 KRW
9/24/2025137,900.00 KRW
9/23/2025141,200.00 KRW
9/22/2025139,500.00 KRW
9/19/2025139,000.00 KRW
9/18/2025131,800.00 KRW
9/17/2025131,700.00 KRW
9/16/2025133,200.00 KRW
9/15/2025134,700.00 KRW
9/12/2025134,000.00 KRW
9/11/2025133,300.00 KRW
9/10/2025133,000.00 KRW
9/9/2025132,600.00 KRW
9/8/2025133,800.00 KRW
9/5/2025131,000.00 KRW
9/4/2025131,900.00 KRW
9/3/2025131,100.00 KRW
9/2/2025128,900.00 KRW
9/1/2025128,100.00 KRW
8/29/2025129,700.00 KRW
8/28/2025131,800.00 KRW
8/27/2025133,100.00 KRW
8/26/2025133,100.00 KRW
8/25/2025134,200.00 KRW
8/22/2025130,600.00 KRW
8/21/2025130,300.00 KRW
8/20/2025131,000.00 KRW
8/19/2025131,000.00 KRW
8/18/2025133,200.00 KRW
8/14/2025134,600.00 KRW
8/13/2025135,400.00 KRW
8/12/2025133,800.00 KRW
8/11/2025134,300.00 KRW
8/8/2025134,600.00 KRW
8/7/2025137,700.00 KRW
8/6/2025137,100.00 KRW
Access this data via the Eulerpool API
Get Free API Key

GC Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.50 T KRW
50.25 B KRW
81.05 B KRW
Jan 1, 2021
1.54 T KRW
73.66 B KRW
123.21 B KRW
Jan 1, 2022
1.71 T KRW
81.26 B KRW
65.45 B KRW
Jan 1, 2023
1.63 T KRW
34.44 B KRW
-26.63 B KRW
Jan 1, 2024
1.68 T KRW
32.11 B KRW
-26.28 B KRW
Jan 1, 2025 (e)
1.99 T KRW
76.84 B KRW
26.16 B KRW
Jan 1, 2027 (e)
2.12 T KRW
81.88 B KRW
59.31 B KRW
Jan 1, 2028 (e)
2.29 T KRW
88.39 B KRW
92.15 B KRW

GC Biopharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 1:40 PM
 
REVENUET KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2027e2028e
0.810.890.981.051.201.291.331.361.501.541.711.631.681.992.122.29
5.719.419.817.4314.327.513.651.6710.832.2411.28-4.953.2718.356.567.95
31.2430.9531.8432.3529.3928.4825.9127.4229.2933.8534.0029.7928.6928.6928.6928.69
253.58274.89310.50339.00352.08366.80345.87372.17440.63520.59581.80484.63481.93570.38607.82656.14
74.3678.8196.9791.6878.4590.3050.1541.6850.2573.6681.2634.4432.1176.8481.8888.39
9.168.879.948.756.557.013.763.073.344.794.752.121.913.863.863.86
53.6470.0783.9594.9762.9753.2534.43-3.6481.05123.2165.45-26.63-26.2826.1659.3192.15
-3.1130.6219.8113.13-33.69-15.44-35.34-110.57-2,327.8452.02-46.88-140.69-1.32-199.52126.7755.36
1,250.001,250.001,250.001,750.001,250.001,250.001,000.001,000.001,500.002,000.001,750.001,500.001,500.003,600.004,320.005,184.00
-16.67––40.00-28.57–-20.00–50.0033.33-12.50-14.29–140.0020.0020.00
11.0011.0012.0012.0012.0011.0011.0011.0011.0011.4111.4111.4111.4111.4111.4111.41
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales GC Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue GC Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare GC Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares GC Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against GC Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

GC Biopharma stock margins

The GC Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GC Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GC Biopharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
29.29 %
3.34 %
5.39 %
Jan 1, 2021
33.85 %
4.79 %
8.01 %
Jan 1, 2022
34.00 %
4.75 %
3.82 %
Jan 1, 2023
29.79 %
2.12 %
-1.64 %
Jan 1, 2024
28.69 %
1.91 %
-1.56 %
Jan 1, 2025 (e)
28.69 %
3.86 %
1.32 %
Jan 1, 2027 (e)
28.69 %
3.86 %
2.80 %
Jan 1, 2028 (e)
28.69 %
3.86 %
4.03 %

GC Biopharma Stock Revenue, EBIT, Earnings per Share

The GC Biopharma earnings per share therefore indicates how much revenue GC Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
136,737.73 KRW
4,568.45 KRW
7,368.09 KRW
Jan 1, 2021
134,740.97 KRW
6,454.07 KRW
10,795.55 KRW
Jan 1, 2022
149,941.53 KRW
7,120.15 KRW
5,734.86 KRW
Jan 1, 2023
142,523.03 KRW
3,017.22 KRW
-2,333.42 KRW
Jan 1, 2024
147,188.52 KRW
2,813.18 KRW
-2,302.62 KRW
Jan 1, 2025 (e)
174,202.66 KRW
6,732.59 KRW
2,291.71 KRW
Jan 1, 2027 (e)
185,636.42 KRW
7,174.49 KRW
5,196.83 KRW
Jan 1, 2028 (e)
200,393.58 KRW
7,744.82 KRW
8,073.69 KRW

GC Biopharma business model & stock analysis

GC Biopharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

GC Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

GC Biopharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

GC Biopharma shares outstanding

The number of shares of GC Biopharma was 11.41 M in 2025. This indicates how many shares GC Biopharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
11.00 M Stocks
Jan 1, 2021
11.41 M Stocks
Jan 1, 2022
11.41 M Stocks
Jan 1, 2023
11.41 M Stocks
Jan 1, 2024
11.41 M Stocks
Jan 1, 2025 (e)
11.41 M Stocks
Jan 1, 2027 (e)
11.41 M Stocks
Jan 1, 2028 (e)
11.41 M Stocks

GC Biopharma stock splits

In GC Biopharma's history, there have been no stock splits.

GC Biopharma Dividend History

27 years of dividend payments

YearAnnual DividendYoY ChangePayments
20261,500.00KRWYTD—1×
Mar 30, 20261,500.00KRW 0.0%1/1
20241,500.00KRW 0.0%1×
20231,500.00KRW↓ 14.3%1×
20221,750.00KRW↓ 12.5%1×
20212,000.00KRW↑ 33.3%1×
20201,500.00KRW↑ 50.0%1×
20191,000.00KRW 0.0%1×
20181,000.00KRW↓ 20.0%1×
20171,250.00KRW 0.0%1×
20161,250.00KRW↓ 28.6%1×

GC Biopharma dividend history and estimates

In 2025, GC Biopharma paid a dividend amounting to 3,600.00 KRW. Dividend means that GC Biopharma distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
1,500.00 KRW
0.00 KRW
Jan 1, 2021
2,000.00 KRW
0.00 KRW
Jan 1, 2022
1,750.00 KRW
0.00 KRW
Jan 1, 2023
1,500.00 KRW
0.00 KRW
Jan 1, 2024
1,500.00 KRW
0.00 KRW
Jan 1, 2025 (e)
0.00 KRW
3,600.00 KRW
Jan 1, 2027 (e)
0.00 KRW
4,320.00 KRW
Jan 1, 2028 (e)
0.00 KRW
5,184.00 KRW

GC Biopharma dividend payout ratio

In 2025, GC Biopharma had a payout ratio of 157.09%. The payout ratio indicates the percentage of the company's profits that GC Biopharma distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
20.36 %
Jan 1, 2021
18.53 %
Jan 1, 2022
30.52 %
Jan 1, 2023
-64.28 %
Jan 1, 2024
-65.14 %
Jan 1, 2025 (e)
157.09 %
Jan 1, 2027 (e)
83.13 %
Jan 1, 2028 (e)
64.21 %

Current GC Biopharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
7.89 %
Buy
93.75 % (15)
Hold
6.25 % (1)
Sell
0.00 % (0)
12M Price Target
209,100.00
Last Price
112,700.00
Currency
KRW
12M Return Potential
85.54 %
LTM Return
0 %

GC Biopharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/30/2024854.26KRW-384.76 BKRW-2024 Q1
2/12/2024-256.77KRW-425.08 BKRW-2023 Q4

EESG©

Eulerpool ESG Scorecard© for the GC Biopharma stock

84/100
99
Environment
99
Social
54
Governance
E

Environment

20
Scope 1 - Direct Emissions10,804
Scope 2 - Indirect emissions from purchased energy54,001
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions64,804
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees26.012
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

GC Biopharma shareholder structure

% Name
1.43417%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.65960%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.49147%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.46657%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.38062%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.37030%
Bessemer Trust Company, N.A. (US)
Bessemer Trust Company, N.A. (US)

GC Biopharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
47.8%
Float Shares
-
Shares Outstanding
-

GC Biopharma Executives and Management Board

13 members · avg. age 57 · 8 % women

EH

Mr. Eun Cheol Huh (52)

President, Chief Executive Officer, Director · since 2010

899.00 M KRW

Management

YL

Mr. Yeong Tae Lee (66)

Internal Auditor

–
YL

Mr. Yin Gyu Lee (51)

Head of Factory of Hwasun Factory

–
HP

Mr. Hyeong Jun Park (50)

Head of Factory of Ochang Factory

–
SK

Mr. Seong Yeol Kim (49)

IR Contact Officer · since 2023

–

Board of Directors

YH

Mr. Yil Seop Huh (69)

Chairman · since 2004

950.00 M KRW
JJ

Mr. Jae Wuk Jung (60)

Director

–
WS

Mr. Wung Shin (52)

Director

–
SY

Mr. Seung Ho Yim (62)

Director · since 2020

–
CL

Mr. Chun Wu Lee (57)

Non-Executive Independent Director

–
JL

Ms. Jin Hui Lee (50)

Non-Executive Independent Director

–

Frequently asked questions about GC Biopharma

Analysts currently set an average price target of 208,386.00 KRW for the GC Biopharma stock (median: 209,100.00 KRW), implying +84.9 % versus the latest price. The consensus is based on 16 analyst ratings.

GC Biopharma Analyst Price Targets 2026

16 analysts currently rate the GC Biopharma stock: 15 recommend buying, 1 holding and 0 selling.

GC Biopharma Analyst Price Targets 2026

Converted at the current exchange rate, the GC Biopharma share trades at 68.50 EUR (112,700.00 KRW).

No history available for GC Biopharma.

The revenue cannot currently be calculated for GC Biopharma.

The profit cannot currently be calculated for GC Biopharma.

The P/E ratio cannot be calculated for GC Biopharma at the moment.

The P/S cannot be calculated for GC Biopharma currently.

The Eulerpool Quality Score for GC Biopharma is 1/10.

The ISIN of GC Biopharma is KR7006280002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of GC Biopharma is 006280.KS. The ticker symbol is used to trade GC Biopharma shares on the stock exchange.

Over the past 12 months, GC Biopharma paid a dividend of 1,500.00 KRW . This corresponds to a dividend yield of about 1.33 %. For the coming 12 months, GC Biopharma is expected to pay a dividend of 4,320.00 KRW.

The current dividend yield of GC Biopharma is 1.33 %.

GC Biopharma pays a dividend, distributed in the months of , , , .

GC Biopharma paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 4,320.00 KRW are expected. This corresponds to a dividend yield of 3.83 %.

GC Biopharma is assigned to the 'Health' sector.

To receive the latest dividend of GC Biopharma from amounting to 1,500 KRW, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, GC Biopharma distributed 3,600 KRW as dividends.

The dividends of GC Biopharma are distributed in KRW.

All fundamentals and in-depth analysis of GC Biopharma

Our stock analysis for GC Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GC Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

GC Biopharma Stock
GC Biopharma Revenue→
GC Biopharma Stock
GC Biopharma Net Income→
GC Biopharma Stock
GC Biopharma P/E→
GC Biopharma Stock
GC Biopharma P/S→
GC Biopharma Stock
GC Biopharma EBIT→
GC Biopharma Stock
GC Biopharma Dividend→
GC Biopharma Stock
GC Biopharma Directors Dealings→
GC Biopharma Stock
GC Biopharma Stocks→
GC Biopharma Stock
GC Biopharma Market capitalization→
GC Biopharma Stock
GC Biopharma Debt→
GC Biopharma Stock
GC Biopharma Liabilities→
GC Biopharma Stock
GC Biopharma Equity→
GC Biopharma Stock
GC Biopharma AAQS→
GC Biopharma Stock
GC Biopharma Employees→
GC Biopharma Stock
GC Biopharma ROE→
GC Biopharma Stock
GC Biopharma ROA→
GC Biopharma Stock
GC Biopharma ROCE→
GC Biopharma Stock
GC Biopharma News→
GC Biopharma Stock
GC Biopharma Analyst Price Targets→

Health Stocks

GC CellGB SciencesGC GenomeGaush MeditechGE Healthcare TechnologiesGarrison Film ProductionsGelesis HoldingsGarofalo Health Care SpAGelstatGansu Longshenrongfa Pharmaceutical Industry CoGelteqGan & Lee PharmaceuticalsAll Stocks A–Z →